Human Recombinant Monoclonal SPIKE antibody. Carrier free. Suitable for I-ELISA and reacts with Recombinant fragment - SARS-CoV-2 samples.
IgG1
Human
pH: 7.2 - 7.4
Constituents: 100% PBS
Liquid
Monoclonal
I-ELISA | |
---|---|
Recombinant fragment - SARS-CoV-2 | Tested |
SARS-CoV-2 | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant fragment - SARS-CoV-2 | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species SARS-CoV-2 | Dilution info - | Notes - |
Human Recombinant Monoclonal SPIKE antibody. Carrier free. Suitable for I-ELISA and reacts with Recombinant fragment - SARS-CoV-2 samples.
IgG1
Human
pH: 7.2 - 7.4
Constituents: 100% PBS
Liquid
Monoclonal
Yes
EPR24852-174
Affinity purification Protein A
Blue Ice
1-2 weeks
+4°C
+4°C
This human monoclonal chimeric antibody has been engineered from a RabMAb parent antibody (Anti-SARS-CoV-2 Spike Glycoprotein S1 (RBD) antibody [EPR24852-174] ab283946). By necessity, some rabbit sequence is retained as part of the variable domain. When multiplexing with other rabbit-derived antibodies, using cross absorbed Fc-reactive secondary antibodies are recommended.
ab323458 is the carrier-free version of Anti-SARS-CoV-2 Spike Glycoprotein S1 (RBD) [EPR24852-174] - Human IgG1 (Chimeric) ab323456
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
This supplementary information is collated from multiple sources and compiled automatically.
The SARS-CoV-2 Spike Glycoprotein S1 also known as the G10 spike or glycoprotein spike plays an important role in allowing the virus to attach and enter host cells. This protein with a mass of approximately 180 kDa is located on the surface of the virus and forms the outer spikes observed in coronaviruses. Expression of the spike glycoprotein is in virus-infected cells where it facilitates the interaction with host cell receptors. The S1 subunit includes a receptor-binding domain that specifically binds to the human angiotensin-converting enzyme 2 (ACE2) receptors initiating the infection process.
The spike glycoprotein S1 mediates the fusion of the viral and cellular membranes which is necessary for viral entry. It forms part of a larger trimeric complex comprising S1 and S2 subunits. This complex undergoes conformational changes that drive the membrane fusion process. The glycoprotein contains multiple glycosylation sites which help shield the virus from the host immune response. The proper function and presentation of this glycoprotein are critical for efficient viral spread and infection establishment.
The spike glycoprotein S1 is integral to the viral infection pathway and host immune evasion. It interacts with the renin-angiotensin system by binding to the ACE2 receptor disrupting normal receptor activity. This interaction not only facilitates viral entry but also impacts the homeostatic functions typically mediated by ACE2 which include blood pressure regulation. Additionally the spike protein is involved in downstream activation of immune signaling pathways including those related to inflammation and cytokine production which may involve proteins such as IL-6.
Infection with the spike glycoprotein S1 is directly related to COVID-19. The binding to ACE2 receptors is linked to the pathology of the disease contributing to respiratory symptoms and in severe cases acute respiratory distress syndrome (ARDS). Through the IL-6 signaling pathway the spike protein is indirectly connected to cytokine release syndrome often observed in severe COVID-19 cases. This connection highlights the importance of targeting this glycoprotein for potential therapeutic interventions and diagnostics such as ELISA SARS-CoV-2 tests and the development of anti-spike antibodies available on platforms like antispark.com for research and clinical purposes.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Indirect ELISA- Rabbit monoclonal [EPR24852-174] to SARS-CoV-2 Spike Glycoprotein S1 (RBD) - Human IgG1 (Chimeric) (Anti-SARS-CoV-2 Spike Glycoprotein S1 (RBD) [EPR24852-174] - Human IgG1 (Chimeric) ab323456).
Indirect ELISA showing primary antibody Anti-SARS-CoV-2 Spike Glycoprotein S1 (RBD) [EPR24852-174] - Human IgG1 (Chimeric) ab323456 binding to Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera, Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera) ab272105) and Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein RBD (His tag). Plates were coated with Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera, Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera) ab272105), Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein RBD (His tag) and SARS-CoV Spike S1+S2 ECD-His Recombinant Protein at 1000 ng/ml. Binding of Anti-SARS-CoV-2 Spike Glycoprotein S1 (RBD) [EPR24852-174] - Human IgG1 (Chimeric) ab323456 was assessed in a serial dilution range 0.016- 1000 ng/mL (a 3-fold serial dilution). Secondary antibody, Goat Anti-Human IgG Fc (HRP) preadsorbed (Goat Anti-Human IgG Fc (HRP) preadsorbed ab98624) was used at 1:5000.
This data was developed using the same antibody clone in a different buffer formulation.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com